Immunotherapy for non-small cell lung cancer (NSCLC) is incorporated increasingly in first
line treatments protocols. Multiple phase 3 studies have tested different medications …

Background Patients with non-small cell lung cancer (NSCLC) and preexisting interstitial
lung disease (ILD) are often excluded from clinical trials of immune checkpoint inhibitors …

Abstract Background and Objective There remains a paucity of large databases for patients
with idiopathic pulmonary fibrosis (IPF) and lung cancer. We aimed to create a European …

Non-small cell lung cancer (NSCLC) represents the most common and fatal type of primary
lung malignancies. NSCLC is often diagnosed at later stages and requires systemic …

The coexistence of lung adenocarcinoma (LUAD) with idiopathic pulmonary fibrosis (IPF),
which has been extensively documented as a prominent risk factor for checkpoint inhibitor …

Patients with progressive fibrosing interstitial lung diseases (fILD) have increased morbidity
and mortality. Lung fibrosis can be associated with lung cancer. The pathogenesis of both …

Objectives: Chronic obstructive pulmonary disease (COPD) is the most common co-
morbidity associated with non-small cell lung cancer (NSCLC) patients. Immune checkpoint …

Abstract Background Immune checkpoint inhibitors (ICIs) have demonstrated efficacy over
previous cytotoxic chemotherapies in clinical trials among various tumors. Despite their …

Introduction: The development of immune checkpoint inhibitors (ICIs) has been a
breakthrough in the treatment of several types of cancer. With the widespread use of ICIs in …

Immune checkpoint inhibitors (ICIs) have shown definite therapeutic effects in various types
of cancers, especially non-small cell lung cancer (NSCLC). However, ICIs have unique side …